相关实验视频

Updated: Jun 6, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

新合成的Citral衍生物作为HepG2细胞中的新兴抑制剂

Wei Gao¹, Xiaoju Hua¹, Shengliang Liao²

¹Camphor Engineering Research Center of National Forestry and Grassland Administration, Jiangxi Academy of Forestry, Nanchang, 330032, China.

|November 27, 2024

概括

一种新型的pyranopyridine衍生物,化合物3h,有效地抑制了HepG2肝癌细胞的生长,并诱导了亡. 这种化合物通过向关键的生存途径,显示出作为潜在的抗癌药物的前景.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
有机合成有机合成

背景情况:

肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战.
开发具有提高疗效和降低毒性的新型治疗剂至关重要.
皮拉诺皮里丁衍生物代表了一类具有潜在抗癌活性的化合物.

研究的目的:

为了合成新型的阿里化皮拉诺皮里丁衍生物.
为了评估这些衍生物对HepG2肝癌细胞的抗癌活性.
阐明底层的分子作用机制.

主要方法:

合成2H-pyran化合物1及其随后的N-arylation.
使用HepG2细胞进行体外抗增殖试验.
细胞循环分析,细胞亡测定 (例如,BAX和BCL2的西方涂抹).
对关键信号通路 (PI3K/Akt,MAPK/ERK) 的分析.

主要成果:

亚利 pyranopyridine 衍生物被成功合成,产量高达 77%.
化合物3h显示出对HepG2细胞的强烈抑制 (IC50 = 5.3μM),表现优于西斯.
3小时诱导S相细胞周期停止和显著的细胞亡,上调BAX和下调BCL2.
观察到PI3K/Akt和MAPK/ERK信号通路的抑制.

结论:

化合物3h对HepG2肝癌细胞表现出显著的抗癌作用.
该机制涉及诱导亡和抑制关键生存信号通路.
3h代表了一种有前途的化合物,用于开发新的肝癌治疗方法.

关键词:

这是一种抗癌药物.细胞亡是细胞的亡.在Citral中,我们可以看到Citral.衍生品是一种衍生品.肝癌细胞是HepG2肝癌细胞.

更多相关视频

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...